Sardegna
In Sardegna region 75% of women (aged 24-64) are screened regularly, meaning every 3 years. The analysis on cross-protective activity exercised by bivalent and quadrivalent vaccines shows that the bivalent vaccine could prevent more pre-cancerous lesions and cases of cervicocarcinoma than quadrivale...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd Medical Publishers
2012-11-01
|
| Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/464 |
| _version_ | 1818313856622002176 |
|---|---|
| author | Roberto Gasparini Donatella Panatto Bruna Dirodi Rosa Prato Gianni Amunni Valter Turello Luigi Sudano Paolo Cristoforoni Sara Boccalini Paolo Bonanni |
| author_facet | Roberto Gasparini Donatella Panatto Bruna Dirodi Rosa Prato Gianni Amunni Valter Turello Luigi Sudano Paolo Cristoforoni Sara Boccalini Paolo Bonanni |
| author_sort | Roberto Gasparini |
| collection | DOAJ |
| description | In Sardegna region 75% of women (aged 24-64) are screened regularly, meaning every 3 years. The analysis on cross-protective activity exercised by bivalent and quadrivalent vaccines shows that the bivalent vaccine could prevent more pre-cancerous lesions and cases of cervicocarcinoma than quadrivalent, and that the latter could prevent genital warts that are not prevented by bivalent. The major number of cases avoided by the bivalent make it possible to fully offset the cost savings related to warts associated with the quadrivalent vaccine. Furthermore, a cost-effectiveness analysis shows that, considering regional tariffs, the multiple cohort (12-year-old + 25-year-old women) vaccination strategy with a 90% coverage could prevent 17 cases of cervicocarcinoma and 8 related deaths more than the vaccination of only 12-year-old girls, and thus proves to be cost-effective (10,841 €/QALY). |
| first_indexed | 2024-12-13T08:40:24Z |
| format | Article |
| id | doaj.art-194cd64ab29c433ab09a61b789daf0ae |
| institution | Directory Open Access Journal |
| issn | 2240-256X |
| language | English |
| last_indexed | 2024-12-13T08:40:24Z |
| publishDate | 2012-11-01 |
| publisher | SEEd Medical Publishers |
| record_format | Article |
| series | Farmeconomia: Health Economics and Therapeutic Pathways |
| spelling | doaj.art-194cd64ab29c433ab09a61b789daf0ae2022-12-21T23:53:33ZengSEEd Medical PublishersFarmeconomia: Health Economics and Therapeutic Pathways2240-256X2012-11-01132S586010.7175/fe.v13i2S.464429SardegnaRoberto Gasparini0Donatella Panatto1Bruna Dirodi2Rosa Prato3Gianni Amunni4Valter Turello5Luigi Sudano6Paolo Cristoforoni7Sara Boccalini8Paolo Bonanni9Dipartimento di Scienze della Salute, Università di GenovaDipartimento di Scienze della Salute, Università di GenovaDirezione Access to Medicine, GlaxoSmithKline, VeronaDipartimento di Scienze Mediche e Chirurgiche, Università degli Studi di FoggiaDipartimento di Ginecologia, Perinatologia e Riproduzione Umana, Università di FirenzeDipartimento di Prevenzione U.O. Igiene e Sanità Pubblica, Azienda USL 3 GenovaAssessorato Sanità, Salute e Politiche Sociali, Servizio Igiene, Sanità Pubblica, Veterinaria e degli Ambienti di lavoroDipartimento di Oncologia Ginecologica, Istituto Nazionale per la Ricerca sul Cancro, GenovaDipartimento di Sanità Pubblica, Università di FirenzeDipartimento di Sanità Pubblica, Università di FirenzeIn Sardegna region 75% of women (aged 24-64) are screened regularly, meaning every 3 years. The analysis on cross-protective activity exercised by bivalent and quadrivalent vaccines shows that the bivalent vaccine could prevent more pre-cancerous lesions and cases of cervicocarcinoma than quadrivalent, and that the latter could prevent genital warts that are not prevented by bivalent. The major number of cases avoided by the bivalent make it possible to fully offset the cost savings related to warts associated with the quadrivalent vaccine. Furthermore, a cost-effectiveness analysis shows that, considering regional tariffs, the multiple cohort (12-year-old + 25-year-old women) vaccination strategy with a 90% coverage could prevent 17 cases of cervicocarcinoma and 8 related deaths more than the vaccination of only 12-year-old girls, and thus proves to be cost-effective (10,841 €/QALY).https://journals.seedmedicalpublishers.com/index.php/FE/article/view/464hpvvaccination strategyscreeningsardegnacost-effectiveness analysis |
| spellingShingle | Roberto Gasparini Donatella Panatto Bruna Dirodi Rosa Prato Gianni Amunni Valter Turello Luigi Sudano Paolo Cristoforoni Sara Boccalini Paolo Bonanni Sardegna Farmeconomia: Health Economics and Therapeutic Pathways hpv vaccination strategy screening sardegna cost-effectiveness analysis |
| title | Sardegna |
| title_full | Sardegna |
| title_fullStr | Sardegna |
| title_full_unstemmed | Sardegna |
| title_short | Sardegna |
| title_sort | sardegna |
| topic | hpv vaccination strategy screening sardegna cost-effectiveness analysis |
| url | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/464 |
| work_keys_str_mv | AT robertogasparini sardegna AT donatellapanatto sardegna AT brunadirodi sardegna AT rosaprato sardegna AT gianniamunni sardegna AT valterturello sardegna AT luigisudano sardegna AT paolocristoforoni sardegna AT saraboccalini sardegna AT paolobonanni sardegna |